We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogene MSCs Transplantation in Liver for Patients With Chronic Liver Diseases Through Portal Vein by Ultrasound Guiding

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01256138
Recruitment Status : Unknown
Verified October 2010 by Sun Yat-sen University.
Recruitment status was:  Recruiting
First Posted : December 8, 2010
Last Update Posted : December 8, 2010
Sponsor:
Information provided by:
Sun Yat-sen University

Brief Summary:
Allogene MSCs transplantation will be performed in patients with chronic liver diseases through portal vein by ultrasound guiding and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.

Condition or disease
Allogene Transplantation Chronic Liver Diseases Patients Through Portal Vein by Ultrasound Guiding

Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Case Control
Time Perspective: Retrospective
Study Start Date : October 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Diseases
U.S. FDA Resources

Group/Cohort
transplantation
control



Primary Outcome Measures :
  1. Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation [ Time Frame: 1-8 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease and so on.
Criteria

Inclusion Criteria:

  1. chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease.
  2. age: 15-65 years old.

Exclusion Criteria:

  1. pregnant women and women in lactation.
  2. other systems and organs disfunction
  3. space-occupying lesion were found in liver.
  4. concurrent infection with HIV and other immunodeficiency diseases.
  5. DIC and active bleeding were confirmed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01256138


Locations
China, Guangdong
Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University Recruiting
Guangzhou, Guangdong, China, 510630
Contact: Liang Peng, Dr.    +86-013533978874    pzp33@hotmail.com   
Contact: Jing Liu, Master.    +86-013556051920    diudiu1203@163.com   
Sponsors and Collaborators
Sun Yat-sen University

Responsible Party: Zhi-liang Gao, Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT01256138     History of Changes
Other Study ID Numbers: SunYat-sen U 11-5-2
First Posted: December 8, 2010    Key Record Dates
Last Update Posted: December 8, 2010
Last Verified: October 2010

Keywords provided by Sun Yat-sen University:
Allogene MSCs
transplantation
chronic liver diseases
portal vein

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases